Company Filing History:
Years Active: 2017-2022
Title: Frank V Cochran: Innovator in Knottin Mini-Proteins
Introduction
Frank V Cochran is a notable inventor based in Stanford, CA (US). He has made significant contributions to the field of biochemistry, particularly in the development of knottin mini-proteins. With a total of 3 patents to his name, Cochran's work is paving the way for advancements in therapeutic applications.
Latest Patents
Cochran's latest patents focus on "Conjugated knottin mini-proteins containing non-natural amino acids." These patents disclose knottin peptides that incorporate non-natural amino acids, allowing for chemical conjugation into multiple knottin monomers. The knottin monomers include a non-natural amino acid, such as an aminooxy residue, within their polypeptide sequence. The exemplified dimers were produced through oxime formation between two aldehyde groups on a polyether linker and an aminooxy functional group that was site-specifically incorporated into the knottin. Variants based on EETI (trypsin inhibitor) and AgRP (Agouti-related protein) were engineered to contain integrin-binding loops. These dimers demonstrated increased binding strength to integrins on U87MG tumor cells, leading to significant inhibition of cell adhesion and proliferation. Additionally, knottin monomers with an aminooxy residue can be conjugated to therapeutic molecules such as doxorubicin.
Career Highlights
Cochran is affiliated with Leland Stanford Junior University, where he continues to advance his research in the field of protein engineering. His innovative work has garnered attention and respect within the scientific community.
Collaborations
Some of his notable coworkers include Jennifer R Cochran and Jun Woo Kim, who contribute to the collaborative efforts in his research endeavors.
Conclusion
Frank V Cochran's contributions to the field of knottin mini-proteins highlight his innovative spirit and dedication to advancing biochemistry. His work not only enhances our understanding of protein interactions but also opens new avenues for therapeutic applications.